LEGN — LEGEND BIOTECH CORP

Public company

Sign in to save3 tracked investors reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

About LEGEND BIOTECH CORP (LEGN)

LEGEND BIOTECH CORP (LEGN) appears in the most recent 13F filings of 3 tracked institutional investors. The largest disclosed position is held by Steve Cohen (Point72 Asset Management), valued at $70M. All data sourced from SEC 13F filings.

Tracked investors reporting LEGN

  • Steve CohenMar 31, 2026
    Point72 Asset Management
    Shares
    3.9M
    Value
    $70.3M
    % Portfolio
    0.09%
  • Ken GriffinMar 31, 2026
    Citadel Advisors
    Shares
    678.5K
    Value
    $12.3M
    % Portfolio
    0.00%
  • Izzy EnglanderMar 31, 2026
    Millennium Management
    Shares
    284.9K
    Value
    $5.2M
    % Portfolio
    0.00%

Recent activity

  • No recent activity.

Frequently asked questions

How many institutional investors hold LEGN?
3 tracked institutional investors disclosed a position in LEGN (LEGEND BIOTECH CORP) in their most recent 13F filing.
Who is the largest institutional holder of LEGN?
Steve Cohen, Point72 Asset Management, holds the largest disclosed position in LEGN, valued at $70M.
Did institutional ownership of LEGN increase or decrease?
Across recent 13F filings, tracked investors recorded 0 new positions, 0 increased, 0 reduced, and 0 fully exited LEGN.
Where does this LEGN ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.